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Summary
 
A G protein–coupled receptor (GPCR) is encoded within the genome of Kaposi’s sarcoma–
associated herpesvirus (KSHV)/human herpesvirus 8, a virus that may be involved in the patho-
genesis of Kaposi’s sarcoma and primary effusion lymphomas. KSHV-GPCR exhibits constitu-
tive signaling activity that causes oncogenic transformation. We report that human interferon
(IFN)-
 
g
 
–inducible protein 10 (HuIP-10), a C-X-C chemokine, specifically inhibits signaling of
KSHV-GPCR. In contrast, monokine induced by IFN-
 
g
 
 (HuMig), which like HuIP-10 is an
agonist of C-X-C chemokine receptor 3, does not inhibit KSHV-GPCR signaling. Moreover,
HuIP-10, but not HuMig, inhibits KSHV-GPCR–induced proliferation of NIH 3T3 cells.
These results show that HuIP-10 is an inverse agonist that converts KSHV-GPCR from an ac-
tive to an inactive state. Thus, a human chemokine inhibits constitutive signaling and cellular
proliferation that is mediated by a receptor encoded by a human disease-associated herpesvirus.
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aposi’s sarcoma–associated herpesvirus (KSHV)/hu-
man herpesvirus 8 is a gammaherpesvirus that may be
involved in the pathogenesis of Kaposi’s sarcoma (KS; ref-
erence 1) and primary effusion (or body cavity–based) lym-
phomas (2). KSHV contains a gene encoding a G protein–
coupled receptor (KSHV-GPCR; references 3 and 4), and
mRNA transcripts for KSHV-GPCR have been found in
tissues from patients with KS (5) and in cell lines derived
from patients with primary effusion lymphomas (2, 3). We
showed that KSHV-GPCR exhibits constitutive signaling,
that is, signaling in the absence of agonist, via activation of
phosphoinositide-specific phospholipase C (6), and that ex-
pression of KSHV-GPCR stimulates proliferation of rat fi-
broblasts (6) and causes transformation of mouse NIH 3T3
fibroblasts (7) in cell culture. Moreover, NIH 3T3 cells
transformed by KSHV-GPCR form tumors in mice (7).
Thus, KSHV-GPCR may be a mediator of KS-induced
tumorigenesis.
KSHV-GPCR shows homology to human receptors, in-
cluding C-X-C chemokine receptor (CXCR)1, which binds
IL-8, CXCR2, which binds IL-8 as well as several other
C-X-C chemokines (8), and CXCR3, which binds human
IFN-
 
g
 
–inducible protein 10 (HuIP-10) and human mono-
kine induced by IFN-
 
g
 
 (HuMig; references 9 and 10).
However, CXCR1, CXCR2, and CXCR3 do not exhibit
constitutive signaling, although like KSHV-GPCR they
appear to signal via phospholipase C. For example, IL-8 acti-
vation of CXCR1 and CXCR2 stimulates formation of
inositol phosphate second messenger molecules in a mon-
key kidney (COS) cell line (11), and HuIP-10 and HuMig
activation of CXCR3 stimulates elevation of intracellular
calcium, which is likely caused by phospholipase C–medi-
ated generation of inositol 1,4,5-trisphosphate, in several
cell types (9). In contrast, although several chemokines of
the C-X-C and C-C families were shown to bind to
KSHV-GPCR, none was found that would affect KSHV-
GPCR signaling (6). In this report, we show that HuIP-10
(and two HuIP-10 analogues), but not HuMig, inhibits
constitutive signaling of KSHV-GPCR. Thus, HuIP-10 is
an inverse agonist of KSHV-GPCR signaling that converts
the receptor from an active to an inactive state.
 
Materials and Methods
 
Inositol Phosphate Accumulation.
 
KSHV-GPCRs were expressed
in COS-1 and NIH 3T3 cells by transfection with pcKSHV-
GPCR (6) or pCEFL-KSHV-GPCR (7) using the protocols de-
scribed previously. The C-X-C chemokines HuIP-10 and Hu-
Mig, the mouse homologues MuIP-10 and MuMig, and the
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HuIP-10 analogues were chemically synthesized using established
procedures (12).
COS-1 cells transiently transfected with plasmid encoding
KSHV-GPCR (5 
 
m
 
g/ml) or NIH 3T3 cells stably expressing
KSHV-GPCRs were labeled with 
 
myo
 
-[
 
3
 
H]inositol, and the for-
mation of [
 
3
 
H]inositol phosphates during a 90-min incubation
was measured as described (6, 7).
 
Mutagenesis.
 
The full-length KSHV-GPCR cDNA in pc-
DNA3.1(
 
1
 
) (pcKSHV-GPCR; reference 6) was used for muta-
tion. Mutants were prepared by PCR and were subcloned di-
rectly into pcKSHV-GPCR after digesting with EcoRI and
EcoRV. Mutant KSHV-GPCR sequences were confirmed by
the dideoxy chain termination method.
 
Cell Proliferation Assays.
 
KSHV-GPCR–expressing NIH 3T3
cells were grown in DME supplemented with 10% calf serum. DNA
synthesis was measured by incubating KSHV-GPCR–expressing
NIH 3T3 cells in medium supplemented with 1% calf serum and
the indicated concentration of HuIP-10 for 2 d before incubation
with [
 
3
 
H]thymidine (2 
 
m
 
Ci/ml) for 4–6 h.
 
Statistical Analysis.
 
Statistical significance was determined in
each experiment by Student’s 
 
t
 
 test.
 
Results and Discussion
 
Fig. 1 illustrates that HuIP-10 specifically inhibits inosi-
tol phosphate second messenger formation in COS-1 cells
expressing KSHV-GPCRs. The dose of HuIP-10 that
causes 50% inhibition of inositol phosphate formation is 15
nM. HuIP-10 had no effect on inositol phosphate produc-
tion by COS-1 cells that did not express KSHV-GPCRs
(data not shown). These data are consistent with the idea
that HuIP-10 is a specific inverse agonist (or negative an-
tagonist; reference 13) of KSHV-GPCR.
As noted above, HuIP-10 is a ligand for CXCR3, which
also binds HuMig (10). HuIP-10 and HuMig are CXCR3
agonists (9, 14). To further characterize the effects of these
chemokines on KSHV-GPCR signaling, the effects of Hu-
Mig and of the mouse homologues MuIP-10 and MuMig
were determined. MuIP-10, like HuIP-10, inhibits signal-
ing by KSHV-GPCR, whereas HuMig and MuMig have
no effect on KSHV-GPCR signaling (Fig. 1). Thus, the
IP-10 homologues are inverse agonists, whereas the Mig ho-
mologues exhibit no detectable activity at KSHV-GPCR.
HuIP-10 is a 77–amino acid polypeptide. To gain insight
into the structural domain of HuIP-10 involved in inhibition
of KSHV-GPCR signaling, two analogues truncated at the
NH
 
2
 
 terminus were studied. HuIP-10(4–77) and HuIP-
10(9–77) are lacking the first three or eight amino acid resi-
dues, respectively, of HuIP-10. Both HuIP-10(4–77) and
HuIP-10(9–77) inhibited KSHV-GPCR signaling although
with lower potencies than HuIP-10 (3- and 10-fold lower,
respectively; Fig. 2 
 
A
 
). Thus, the NH
 
2
 
 terminus of HuIP-10
is not needed for inhibition of KSHV-GPCR signaling. This
is an interesting finding because the agonist activity of several
members of the C-X-C chemokine family, including HuIP-
10, has been shown to be dependent on their NH
 
2
 
-terminal
domains (8). For example, deletion of the NH
 
2
 
 terminus of
IL-8 causes loss of agonist activity and forms peptides that act
as competitive antagonists (15). The active domain (or phar-
macophore) for inhibition of KSHV-GPCR signaling is not
part of the NH
 
2
 
 terminus of HuIP-10.
It has been found that the putative extracellular NH
 
2
 
 ter-
mini of CXCR1 and CXCR2 are important for interacting
with IL-8 (16). Therefore, we constructed a mutant KSHV-
GPCR in which amino acid residues from positions 2–11
were deleted [KSHV-GPCR(
 
D
 
2–11)]. This mutant recep-
tor exhibited constitutive signaling activity that was 70% (
 
P
 
.
 
0.005) of that of KSHV-GPCR (Fig. 2 
 
B
 
). Therefore,
residues within the NH
 
2
 
 terminus may affect constitutive
signaling by KSHV-GPCR. However, since signaling ac-
tivity is directly related to receptor number (6), it is possible
that the modest decrease in signaling is due to decreased
expression. More importantly, the constitutive signaling
activity exhibited by KSHV-GPCR(
 
D
 
2–11) was not inhib-
ited by HuIP-10. As we have not been able to measure
Figure 1. Effects of HuIP-10
(filled squares), HuMig (filled cir-
cles), MuIP-10 (open squares), and
MuMig (open circles) on constitu-
tive KSHV-GPCR signaling.
Inositol phosphate accumulation
in COS-1 cells transiently trans-
fected with plasmid encoding
KSHV-GPCR was measured as
described in Materials and Meth-
ods. Chemokine analogues were
added at the concentrations indicated 15 min before LiCl (10 mM). Un-
transfected cells and cells transfected with plasmid without DNA encod-
ing KSHV-GPCR (“mock”) or with plasmid encoding the receptor for
thyrotropin-releasing hormone were studied in parallel. There was no ef-
fect of any of these chemokines on inositol phosphate production in un-
transfected cells, in mock-transfected cells, or in cells expressing thyrotro-
pin-releasing hormone receptors (not shown). The dose of HuIP-10 that
caused 50% inhibition of inositol phosphate formation was 15 nM (7.2–32
nM, 95% confidence interval). The data represent the mean 6 SD of tripli-
cate determinations in a representative of three experiments.
Figure 2. Effects of trunca-
tions of the NH2 termini of
HuIP-10 and KSHV-GPCR on
inhibition of KSHV-GPCR sig-
naling. Inositol phosphate accu-
mulation in COS-1 cells tran-
siently transfected with plasmid
encoding KSHV-GPCR or
KSHV-GPCR(D2–11) was mea-
sured as described in Materials
and Methods. HuIP-10, HuIP-
10(4–77), or HuIP-10(9–77) was
added at the concentrations indi-
cated 15 min before LiCl (10 mM).
(A) Effect of truncating the NH2
terminus of the ligand HuIP-10.
The data represent the mean 6 SD
of triplicate determinations in a
representative of three experi-
ments. Filled squares, HuIP-10;
open circles, HuIP-10(4–77); filled
triangles, HuIP-10(9–77). (B) Ef-
fect of truncating the NH2 terminus of KSHV-GPCR. The data represent
the mean 6 SD of triplicate determinations in a representative experiment in
which two plasmid clones encoding KSHV-GPCR(D2–11) were tested.
WT, wild-type. 
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specific HuIP-10 binding, perhaps because of binding to
cell surface heparin sulfates (17), we do not know whether
this lack of effect of HuIP-10 is because it does not bind to
KSHV-GPCR(
 
D
 
2–11) or whether it binds but does not
inactivate KSHV-GPCR(
 
D
 
2–11). However, it is clear that
the NH
 
2
 
 terminus of KSHV-GPCR is important for the in-
verse agonist action of HuIP-10.
Fibroblasts may be a good model for the study of
KSHV-GPCR function because fibroblasts are typically
present in KS lesions (1) and KSHV-like viruses are found
in retroperitoneal fibromatosis tissues in monkeys (18). Ex-
pression of KSHV-GPCR results in stimulation of prolifer-
ation of NIH 3T3 fibroblasts (7). Stimulation of the prolifer-
ation of target cells by KSHV-GPCR could be a component
of the pathogenesis of KS or primary effusion lymphomas
(1, 2). To determine whether inhibition of KSHV-GPCR
signaling would inhibit the proliferative response, the ef-
fects of the IP-10 homologues were measured in trans-
fected NIH 3T3 cells stably expressing KSHV-GPCRs.
Fig. 3 (
 
top
 
) illustrates that HuIP-10 and MuIP-10 inhibit
KSHV-GPCR signaling in NIH 3T3 cells, whereas Hu-
Mig and MuMig have no effect. These findings are identi-
cal to those in COS-1 cells. Moreover, HuIP-10 causes
dose-dependent inhibitions of KSHV-GPCR signaling and
stimulated DNA synthesis in these cells (Fig. 3, 
 
bottom
 
).
The concentrations required for 50% inhibition (IC
 
50
 
s) of
these effects are similar: 39 nM for inhibition of inositol
phosphate second messenger formation, and 29 nM for in-
hibition of DNA synthesis. These results indicate that
HuIP-10 is an inverse agonist of constitutive signaling by
KSHV-GPCR in NIH 3T3 cells that inhibits KSHV-
GPCR–stimulated cell proliferation.
IP-10 homologues are CXCR3 agonists (9), but we
show herein that they are inverse agonists at KSHV-
GPCR. In the majority of instances where two GPCRs in-
teract with the same ligand, the receptors respond similarly
to that ligand (19). However, there are examples of muta-
tions of GPCRs engineered in the laboratory that have
changed an antagonist or inverse agonist into a partial ago-
nist (20, 21). The different effects of the IP-10 homologues
at KSHV-GPCR and CXCR3 may represent a related cir-
cumstance in which a pirated mammalian receptor is mu-
tated within a virus and is then antagonized by a naturally
occurring agonist.
KSHV-GPCR interacts with a much broader array of
chemokines (6) than most mammalian receptors (8). In-
deed, KSHV-GPCR interacts with C-X-C chemokines in-
cluding IL-8, neutrophil activating protein 2, platelet factor
4, melanoma growth stimulatory activity, IP-10 analogues,
and C-C chemokines including regulated on activation,
normal T expressed and secreted (RANTES) and I-309.
However, of these chemokines only the IP-10 analogues
inhibit KSHV-GPCR signaling. It is noteworthy that in ad-
dition to encoding KSHV-GPCR, there are three chemo-
kine analogues encoded within the KSHV genome. One of
these, vMIP-II, is a broad-spectrum antagonist of chemo-
kine receptors (22), but stimulates chemotaxis of eosino-
phils via chemokine receptor CCR3 (23). vMIP-I and
vMIP-II block infection by HIV-1 by binding to chemo-
kine receptors CCR3 and CCR5, and stimulate angiogen-
esis (23). It is not known whether any of these chemokines
affects KSHV-GPCR signaling.
Evidence continues to accumulate supporting the idea
that KSHV is involved in the pathogenesis of KS (1) and
primary effusion lymphomas (2). More recently, it has been
proposed that KSHV could also be involved in the devel-
opment of multiple myeloma (24). From the perspective of
demonstrating a pathogenic role for KSHV-GPCR in
these diseases, it will be important to develop an animal
model and to show that inhibition of KSHV-GPCR sig-
naling inhibits tumorigenesis in KSHV-infected animals.
The discovery of an inhibitor of the constitutive signaling
activity of KSHV-GPCR will allow direct testing in an an-
imal model of the hypothesis that KSHV infection leads to
expression of KSHV-GPCR and KSHV-GPCR signaling
leads to tumorigenesis.
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Figure 3. Inhibition of consti-
tutive KSHV-GPCR signaling
and DNA synthesis in NIH 3T3
mouse fibroblasts. (A) Inositol
phosphate accumulation in NIH
3T3 cells stably expressing
KSHV-GPCRs (reference 7).
HuIP-10, HuMig, MuIP-10, or
MuMig (300 mM) was added 15
min before the addition of LiCl
(10 mM). The data represent the
mean 6 SD of triplicate deter-
minations in one of two experi-
ments. (B) Dose-dependent ef-
fects of HuIP-10 on inositol
phosphate formation (open circles)
and DNA synthesis (filled
squares). The concentration of
HuIP-10 required for 50% inhi-
bition (IC50) of inositol phos-
phate second messenger forma-
tion is 39 nM (9–160 nM; 95%
confidence interval), and for 50% inhibition of DNA synthesis is 29 nM
(8–110 nM, 95% confidence interval). The data represent the mean 6 SE
of triplicate determinations in three experiments. 
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